Investing.com - Cytek Biosciences reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Cytek Biosciences announced earnings per share of $0.04 on revenue of $40.48M. Analysts polled by Investing.com anticipated EPS of $0.01 on revenue of $43.13M.
Cytek Biosciences shares are down 29.95% from the beginning of the year and are trading at $13.70 , down-from-52-week-high.
Cytek Biosciences follows other major Healthcare sector earnings this month
Cytek Biosciences's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar